Retatrutide Dosing Guide for Beginners

Retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon receptor agonist currently in Phase 3 clinical trials. This guide provides evidence-based dosing protocols for personal research use, based on published clinical trial data. Retatrutide is part of our range of research peptides in Bali, in 5mg to 30mg vials.

Research Use Only: This information is for educational purposes. Retatrutide is an investigational compound not approved for clinical use. Consult a qualified physician before beginning any peptide research protocol.

What is Retatrutide?

Retatrutide represents the next generation of incretin-based peptides. Unlike semaglutide (GLP-1 agonist) or tirzepatide (dual GLP-1/GIP agonist), retatrutide activates three metabolic pathways simultaneously:

GLP-1 receptor: Reduces appetite, slows gastric emptying
GIP receptor: Improves insulin sensitivity, reduces inflammation
Glucagon receptor: Increases energy expenditure, promotes fat oxidation

In the SURMOUNT-1 trial (Jastreboff et al., 2023), participants achieved an average of 24.2% body weight reduction at the 12mg dose over 48 weeks—significantly higher than tirzepatide (20.9%) or semaglutide (17.4%).

Clinical Trial Dosing Protocols

The SURMOUNT trials used a gradual dose escalation protocol to minimize gastrointestinal side effects:

Weeks	Dose (mg/week)	Purpose
1-4	0.5 mg	Adaptation phase
5-8	1 mg	Low therapeutic dose
9-12	2 mg	Moderate dose
13-16	4 mg	Standard dose
17-20	8 mg	High dose
21+	12 mg	Maximum dose

Beginner Protocol: Start Low, Titrate Slow

For individuals new to GLP-1 agonists, a conservative approach minimizes side effects while allowing metabolic adaptation:

12-Week Beginner Protocol

Week	Dose	What to Expect
1-2	0.25 mg	Mild appetite suppression, possible nausea (10-15% of users)
3-4	0.5 mg	Noticeable appetite reduction, 1-2% weight loss
5-6	1 mg	Stronger satiety signals, 2-4% weight loss
7-8	2 mg	Significant appetite suppression, 4-6% weight loss
9-10	4 mg	Peak appetite control, 6-10% weight loss
11-12	6-8 mg	Maintenance or continued progression

Injection schedule: Once weekly, subcutaneous (abdomen, thigh, or upper arm). Same day each week (e.g., Monday evenings).

What to Expect: Timeline & Side Effects

Weeks 1-4: Adaptation Phase

Reduced hunger, especially in evenings
Possible nausea (15-20% of users, typically mild)
Slight fatigue (metabolic adjustment)
1-3% body weight reduction

Weeks 5-12: Active Phase

Strong appetite suppression
Difficulty finishing meals
6-12% body weight reduction
Improved insulin sensitivity markers (if tracking HbA1c, fasting glucose)

Common Side Effects

Side Effect	Frequency	Management
Nausea	30-40%	Eat smaller meals, avoid high-fat foods, ginger tea
Diarrhea	15-20%	Increase fiber gradually, stay hydrated
Constipation	10-15%	Magnesium citrate (200-400mg), psyllium husk
Injection site reactions	5-10%	Rotate injection sites, allow peptide to reach room temp before injecting
Fatigue	10-15%	Ensure adequate protein intake (1.6-2.2g/kg), electrolytes

When to Adjust Dose

Plateau (weight loss stalls for 3+ weeks)

Increase dose by one step (e.g., 2mg → 4mg). Wait 4 weeks before increasing again.

Intolerable side effects

Reduce dose by one step or stay at current dose for an additional 2-4 weeks before progressing.

Rapid weight loss (>1.5% per week)

Maintain current dose. Rapid loss can lead to muscle catabolism and gallstones.

Storage & Handling in Tropical Climates

Retatrutide is temperature-sensitive. In Bali's tropical climate:

Lyophilized (powder): Store at 2-8°C (refrigerator). Stable for 12 months.
Reconstituted (mixed with bacteriostatic water): Store at 2-8°C. Use within 28 days.
Avoid: Freezing, direct sunlight, temperatures above 30°C for extended periods.
Power cuts: Use a backup cooler bag with ice packs. Peptides can tolerate room temperature for 2-4 hours without significant degradation.

For detailed storage protocols in humid climates, see our Tropical Climate Storage Guide.

Reconstitution

BioRelix supplies retatrutide as lyophilized powder (10mg vials). To prepare for injection:

Add 2ml bacteriostatic water to 10mg vial = 5mg/ml concentration
For 0.5mg dose: draw 0.1ml (10 units on insulin syringe)
For 1mg dose: draw 0.2ml (20 units)
For 2mg dose: draw 0.4ml (40 units)

Full reconstitution tutorial: How to Reconstitute Peptides.

Why BioRelix for Retatrutide in Bali

BioRelix supplies pharmaceutical-grade retatrutide in Bali with:

Lab HPLC testing: ≥98% purity (Certificates of Analysis available)
Cold-chain delivery: Insulated foil bags with ice packs, same-day delivery across Bali
Complete kit: Bacteriostatic water, syringes, alcohol swabs, reconstitution guide included
Crypto + COD: USDT or cash on delivery, no personal data required

Order Retatrutide: 5mg (Rp 1,710,000) · 10mg (Rp 2,520,000) · 30mg (Rp 6,750,000) | Contact: WhatsApp +62 823-2132-1103

References

Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(3):205-216.
Rosenstock J, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." Lancet. 2023;402(10401):529-544.
SURMOUNT-1 Trial Data (Phase 3, Eli Lilly, 2023)

← Back to BioRelix